AGENUS INC : Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2021-10-22 08:04:19 ET AGEN

Item 8.01 Other Events.

Agenus Inc. (the "Company") announced today a strategic decision to voluntarily withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The decision comes after consultation with the FDA following early full approval of pembrolizumab in second-line cervical cancer. The decision to withdraw the BLA does not change the Company's development plans for use of balstilimab in combination with other therapeutic agents.

The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

--------------------------------------------------------------------------------